Study of IMRT Radiotherapy Concurrent Chemothrerapy for Anal Cancer
Status:
Unknown status
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and adverse events of intensity
modulated radiation therapy (IMRT) concurrent with chemotherapy for anal squamous carcinoma.
All enrolled anal squamous carcinoma patients are intented to receive IMRT concurrent with
Capecitabine + mitomycin ± cetuximab targeted therapy.